Werth, V.; Pike, M.; Merrill, J.; Morand, E.; van Vollenhoven, R.; Hobar, C.; Delev, N.; Shah, V.; Sharkey, B.; Wegman, T.; Catlett, I.; Banerjee, S.; Singhal, S. Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients With Active Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. J of Skin 2023, 7, s114.